Modifiche Registri - VEKLURY (trattamento precoce), mABs e antivirali orali Covid-19 (lagevrio)

AIFA: no effective antibiotics against COVID-19

Monitoring of monoclonal antibodies for COVID-19: weekly report published

EMA receives application for conditional marketing authorisation for Paxlovid for treating patients with COVID-19

AIFA approves Comirnaty booster dose for 12-15 year olds

Monitoring of monoclonal antibodies for COVID-19: weekly report published

Attivazione web e pubblicazione schede di monitoraggio - Registro VEKLURY Trattamento precoce - COVID-19

Attivazione web e pubblicazione schede di monitoraggio - Registro Antivirali orali COVID-19 - LAGEVRIO (MOLNUPIRAVIR)

Monitoring of monoclonal antibodies for COVID-19: weekly report published

Molnupiravir and remdesivir available for the treatment of non-hospitalized COVID-19 patients at high risk of progressing to severe disease

EMA recommends Nuvaxovid for authorisation in the EU

Monitoring of monoclonal antibodies for COVID-19: weekly report published

AIFA approves Novavax’s Covid-19 Vaccine Nuvaxovid

Monitoring of monoclonal antibodies for COVID-19: weekly report published

EMA recommends approval for use of Kineret in adults with COVID-19

EMA issues advice on use of Paxlovid (PF-07321332 and ritonavir) for the treatment of COVID-19

COVID-19: EMA recommends authorisation of antibody medicine Xevudy

EMA reviewing new data on effectiveness of Lagevrio (molnupiravir) for the treatment of COVID-19

COVID-19 Vaccine Janssen: EMA recommendation on booster dose

Monitoring of monoclonal antibodies for COVID-19: weekly report published